{"transactions":[{"id":967741,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-17T00:37:06.000Z","date":"2025-12-12","kind":"sale","planned":false,"acquired":false,"shares":850,"price":1.455,"value":1236.75,"ownership":{"direct":false,"nature":"AJC Capital, LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"All share and share related information gives retrospective effect to the 1-for-12 reverse stock split effective on August 4, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected for estate and tax planning purposes by AJC Capital, LLC (\"AJC\"). The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 6,394 shares of Common Stock directly held by Allan Camaisa, (ii) 19,860 shares of Common Stock held by AJC, and (iii) 50,698 shares of Common Stock held by Jamir Trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Does not include, (i) 1,526 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by Mr. Camaisa, (ii) 3,915 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, and (iii) 22,887 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by AJC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa is deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa is deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."}],"balance_after":76952,"source":{"system":"sec-edgar","filing":"0001493152-25-028030","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315225028030/ownership.xml","form_type":"4"}},{"id":1326858,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Stock","published_at":"2024-12-19T02:29:33.000Z","date":"2024-12-17","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":1.62,"value":16200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected for tax planning purposes. The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC (\"AJC\"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."}],"balance_after":66712,"source":{"system":"sec-edgar","filing":"0001493152-24-050675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224050675/ownership.xml","form_type":"4"}},{"id":1397970,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Stock","published_at":"2024-09-30T22:53:38.000Z","date":"2024-09-26","kind":"grant","planned":false,"acquired":true,"shares":70155,"price":1.15,"value":80678.25,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"In lieu of cash repayments for payables owed to Mr. Camaisa, 70,155 shares were issued to the reporting person at a price per share of $1.15, the closing price of the issuer's common stock immediately prior to the issuance date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC (\"AJC\"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."}],"balance_after":76712,"source":{"system":"sec-edgar","filing":"0001493152-24-038877","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224038877/ownership.xml","form_type":"4"}},{"id":1473367,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Stock Options (right to buy)","published_at":"2024-06-21T00:56:05.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.215, which is equal to 110% of the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.215, which is equal to 110% of the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":40000,"derivative":{"exercise_price":0.215,"expiration_date":"2029-06-17","underlying":"Common stock"},"source":{"system":"sec-edgar","filing":"0001493152-24-024597","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224024597/ownership.xml","form_type":"4"}},{"id":1688267,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President and Chairman"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-01-05T00:49:28.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 100,000 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023 in consideration of Mr. Camaisa personally guaranteeing the raising of $12,500,000 of Series B preferred stock of Calidi Biotherapeutics, a Nevada corporation (\"Old Calidi\"), in connection with the Agreement and Plan of Merger, as amended (\"Merger Agreement\"), by and among First Light Acquisition Group, Inc., FLAG Merger Sub, Inc. (\"Merger Sub\"), First Light Acquisition Group, LLC, Allan Camaisa and Old Calidi. On September 12, 2023, Merger Sub merged with and into Old Calidi, with Old Calidi surviving the merger. The options were granted in a transaction exempt under Rule 16b-3."}],"balance_after":100000,"derivative":{"exercise_price":1.8,"exercise_date":"2023-12-21","expiration_date":"2033-12-23","underlying":"Common stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-24-001131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001131/ownership.xml","form_type":"4"}}]}